An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 in Patients Previously Treated with T-DM1 in a Genentech-Sponsored T-DM1 Study

Sponsor: Genentech, Inc.

Location(s): United States


This is a global, multicenter, open-label extension study. Patients receiving single-agent T-DM1 or combination T-DM1 administered in combination with paclitaxel or with pertuzumab ± paclitaxel in a Genentech/Roche-sponsored study who completed the parent study or who continue to receive study drug(s) at the time of the parent study closure are eligible for continued treatment on this protocol.